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Abstract
Objective—To determine the effect of cryotherapy on HIV-1 cervical shedding.
Design—Prospective cohort study.
Methods—Five hundred HIV-positive women enrolled at an HIV treatment clinic in Nairobi,
Kenya were screened for cervical cancer. Women diagnosed with cervical intraepithelial neoplasia
stage 2 or 3 (CIN 2/3) by histology were offered cryotherapy treatment. The first 50 women had
cervical swabs taken at baseline and at 2 and 4 weeks following treatment. Swabs were analyzed
for HIV-1 RNA and compared using General Estimating Equation (GEE) with binomial or
Gaussian links.
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Results—Of the 50 women enrolled, 40 were receiving antiretroviral therapy (ART) and 10 were
not receiving ART at the time of cryotherapy and during study follow-up. Among all women, the
odds of detectable cervical HIV-1 RNA did not increase at 2 weeks [odds ratio (OR) 1.18; 95%
confidence interval (CI) 0.65–2.13] or 4 weeks (OR 1.29; 95% CI 0.71–2.33) following
cryotherapy. Among 10 women not receiving ART, the OR of detectable shedding at 2 weeks was
higher, but not statistically significant (OR 4.02; 95% CI 0.53–30.79; P = 0.2), and at 4 weeks
remained unchanged (OR 1.00; 95% CI 0.27–3.74).
Conclusion—There was no increase in detectable cervical HIV-1 RNA among HIV-positive
women after cryotherapy. The risk of HIV-1 transmission after cryotherapy may not be
significant, particularly among women already on ART at the time of cervical treatment. However,
further investigation is needed among women not receiving ART.
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Introduction
In resource-limited settings, `see and treat' has been promoted as an economical and
effective method to detect and treat cervical intraepithelial neoplasia (CIN) [1]. In such a
program, women are examined for cervical neoplasia using visual inspection with acetic
acid (VIA) and are treated on the same day with cryotherapy to remove any cervical lesions
[2]. This method is inexpensive to administer and decreases loss to follow-up by combining
diagnosis and treatment on the same day [3]. As a result, a `see and treat' program can
handle a large number of patients and address the immense backlog of women needing
cervical cancer screening in resource-limited settings.
Many of the same areas where `see and treat' programs are implemented also have high
prevalence of HIV-1 [4], yet the impact of cryotherapy on cervical shedding of HIV-1
among HIV-positive women is unclear. Cervical treatments for CIN 2/3 disease, such as
cryotherapy, may inflame the cervix and cause ulcerations and watery discharge that
increase HIV-1 shedding [5–7]. High levels of HIV-1 cervical shedding may in turn increase
an HIV-1-positive woman's infectivity and risk of HIV-1 transmission to HIV-uninfected
sexual partners [8].
In order to understand the effect cryotherapy may have on cervical HIV-1 shedding, we
examined HIV-1 RNA cervical levels over 4 weeks among HIV-positive women receiving
cryotherapy treatment at an HIV treatment clinic in Kenya.
Methods
Five hundred HIV-1-positive women who were enrolled at the Coptic Hope Center for
Infectious Diseases in Nairobi, Kenya were invited to participate in a trial comparing
cervical cancer screening methods [9]. Enrollment and clinic procedures for HIV care at the
Coptic Hope Center have been described previously [10]. Women were eligible to
participate in the cervical screening study if they were at least 18 years of age, had an intact
cervix, were HIV-positive, and had never had cervical treatment for cancerous or
precancerous lesions. The study protocol was reviewed and approved by the institutional
review boards at the University of Washington (Seattle, Washington, USA) and Kenyatta
National Hospital (Nairobi, Kenya). After signing an informed consent, all women
underwent Papanicolaou (Pap) smear, VIA, human papillomavirus (HPV) testing, and
colposcopy-directed biopsy. Blood was also drawn for CD4 cell count and urine pregnancy
test was performed.
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In a subset analysis, the first 50 women in the trial who were diagnosed with CIN 2/3 by
histology and received cryotherapy treatment had cervical swabs and blood samples
obtained at baseline before cryotherapy and then at 2 and 4 weeks after the intervention. To
obtain the cervical specimens, Dacron swabs (Puritan, Guilford, Maine, USA) were inserted
1 cm into the cervical os, the site of cryotherapy treatment, and rotated one full turn [11].
One swab was kept dry in a 2-ml vial and one swab was placed in a 2-ml vial containing 1
ml of solution (70% RPMI, 20% fetal bovine serum, and 10% dimethyl sulfoxide). Cervical
and plasma samples were frozen at −80°C and shipped to Seattle on dry ice for HIV-1 RNA
quantitation.
In Seattle, dry swab samples were thawed into 500 μl of guanadinium lysis buffer [4 mol
guanadinium thiocyanate/l, 25 mmol sodium citrate/l (pH 7), 0.5% N-lauroylsarcosine, and
0.1 mol 2-mercaptoethanol/l] for 15 min at ambient temperatures and vortexed briefly before
HIV-1 RNA was extracted with silica gel to remove inhibitory factors [12]. The swabs
placed in RPMI solution remain in storage for future viral analyses. HIV-1 RNA was
quantified using an independently validated TaqMan real-time PCR assay as previously
described [13]. The lower limit of HIV-1 quantification for plasma was 30 (1.48 log10)
HIV-1 RNA copies/ml and for cervical swabs was 210 (2.32 log10) HIV-1 RNA copies/ml
of swab fluid. Viral levels that were measured below the lower limit of detection were
assigned a value at the midpoint between the lower limit of detection and zero. CD4 cell
counts were determined using flow cytometry (FACScan; Becton Dickinson, Franklin
Lakes, New Jersey, USA).
Viral levels were compared at different time points using General Estimating Equations
(GEE) with binomial (for binary outcome) or Gaussian (for continuous outcome) links,
exchangeable correlation structures, and robust variance estimates.
Results
Between June and November 2009, 500 women were enrolled in the cervical screening
study, 498 completed testing, and 101 received cryotherapy after being diagnosed with CIN
2 (n=40) or 3 (n=61). Of these women, 50 were examined in this subset analysis and had
blood and cervical specimens collected at baseline, 2, and 4 weeks after treatment.
The median age of the 50 study participants was 38 years [interquartile range (IQR) 34–45],
the median CD4 cell count was 296 cells/μl (IQR 178–403), and 23 women (64%) had only
one sexual partner in their lifetime (Table 1). Of the 50 women, 40 were receiving
antiretroviral therapy (ART) (median duration, 529 days; IQR 108–1048) at the time of
cryotherapy, whereas 10 had never received ART and were not receiving ART at the time of
cryotherapy or during the subsequent 4-week follow-up period. Of the women receiving
ART, 34 were on a nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimen of
either nevirapine or efavirenz, and six were on a ritonavir-boosted protease inhibitor-based
regimen of either lopinavir or saquinavir. None were pregnant.
Among all 50 participants, cervical HIV-1 RNA was detected in 18 of 50 (36%) women at
baseline, 19 of 48 (40%) at 2 weeks, and 21 of 50 (42%) at 4 weeks after cryotherapy. The
odds of detectable cervical shedding did not increase at either 2 weeks [odds ratio (OR)
1.18; 95% confidence interval (CI) 0.65–2.13] or 4 weeks (OR 1.29; 95% CI 0.71–2.33)
following treatment. Cervical mean log10 HIV-1 RNA at baseline was 2.64 copies/ml (95%
CI 2.39–2.90) and did not differ significantly at 2 weeks (2.58 copies/ml; 95% CI 2.33–2.84;
P=0.7) or 4 weeks (2.64 copies/ml; 95% CI 2.38–2.90; P=1.0) following cryotherapy.
Among the 40 women receiving ART, cervical HIV-1 RNA was detected in 11 of 40 (28%)
at baseline, 11 of 39 (28%) at 2 weeks, and 14 of 40 (35%) at 4 weeks after cryotherapy.
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The OR of cervical HIV-1 RNA shedding did not increase at either 2 weeks (OR 1.01; 95%
CI 0.46–2.23) or 4 weeks (OR 1.42; 95% CI 0.67–3.02) following treatment. Cervical mean
log10 HIV-1 RNA at baseline was 2.43 copies/ml (95% CI 2.20–2.66) and did not differ
significantly at 2 weeks (2.30 copies/ml; 95% CI 2.14–2.45; P=0.2) or 4 weeks (2.43 copies/
ml; 95% CI 2.21–2.64; P=1.0) following cryotherapy (Fig. 1).
Among the 10 ART-naive women, cervical HIV-1 RNA was detected in seven of 10 (70%)
at baseline, nine of 10 (90%) at 2 weeks, and seven of 10 (70%) at 4 weeks after
cryotherapy. The OR of detectable shedding at 2 weeks after treatment was higher than that
at baseline, but this was not statistically significant (OR 4.02; 95% CI 0.53–30.79), and at 4
weeks, the OR remained unchanged (OR 1.00; 95% CI 0.27–3.74). Cervical mean log10
HIV-1 RNA at baseline was 3.48 copies/ml (95% CI 2.71–4.25) and did not differ
significantly at 2 weeks (3.83 copies/ml; 95% CI 2.95–4.71; P=0.5) or 4 weeks (3.50 copies/
ml; 95% CI 2.65–4.36; P=1.0) following cryotherapy (Fig. 1).
Plasma HIV-1 RNA levels were significantly associated with cervical HIV-1 RNA
detection. For every 1-log10 increase in plasma HIV-1 RNA viral load, there was a 1.97-fold
increased OR of detecting cervical HIV-1 RNA (95% CI 1.40–2.78; P < 0.001).
Discussion
In this study, there was no significant increase in detectable cervical HIV-1 RNA shedding
among 50 HIV-positive women who were examined at 2 and 4 weeks following cervical
cryotherapy for CIN 2/3. A majority of these women (80%) had been receiving ART at the
time of cervical treatment and during study follow-up. Among the small subgroup of 10
women who had not received ART, there was an increase from baseline in detectable
cervical viral shedding at 2 weeks following cryotherapy, but this was not statistically
significant. A strong association between increased plasma HIV-1 RNA level and detection
of cervical HIV-1 RNA was also demonstrated.
In a study by Wright et al. [5], increased cervical shedding of HIV-1 RNA was found among
HIV-positive women treated with cryotherapy, loop electrosurgical excision procedure
(LEEP), and cold-knife cone biopsy; however, the study was limited to 14 women who were
not on ART and no statistical comparisons between time points were presented. Our study
examined a comparatively larger number of women and evaluated a specific homogeneous
cervical treatment intervention (cryotherapy alone) instead of a number of different
interventions (e.g., cryotherapy, LEEP, and biopsy). Most women in our study were also on
ART during cryotherapy, reflecting the composition of a typical cervical cancer screening
program based at an HIV treatment clinic in Africa [4].
ART has been demonstrated to rapidly decrease genital shedding of HIV-1 [14]. These
effects may be due, in part, to a reduction in plasma HIV-1 RNA [15], which was strongly
associated with cervical HIV-1 levels in this study. Over two-thirds of women (70%) not
receiving ART had detectable cervical HIV-1 RNA compared with only 28% of women who
were on ART at the time of cryotherapy. Women on ART in this study also had lower
baseline cervical HIV-1 levels compared to those not receiving ART (mean log10 HIV-1
RNA, 2.43 vs. 3.48 copies/ml), and this more than 1 log10 difference in cervical HIV-1 RNA
was maintained for 4 weeks after cryotherapy. As such, ART may limit cervical HIV-1
RNA shedding associated with tissue damage and inflammation caused by cryotherapy [16]
and thereby decrease the risk of HIV-1 transmission to uninfected sexual partners by more
than half [8].
These results suggest that implementation of `see and treat' programs in Africa may be
safely scaled up in HIV treatment clinics without significant risk of HIV-1 transmission due
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to increased cervical HIV-1 shedding after cryotherapy [17]. However, patients should still
be cautioned against engaging in unprotected sexual activity in the first 2 weeks after
treatment. Among those not taking ART, one strategy could be to prescribe antiretroviral
medications around the time of cryotherapy, similar to how these drugs are administered
during pregnancy to decrease mother-to-child transmission of HIV-1 [18,19].
A limitation of the study is the relatively small numbers of women tested who were not on
ART. There appeared to be a trend for increased shedding at 2 weeks among the 10 women
who were not receiving ART, but this was not statistically significant. This may be due to a
lack of statistical power given the small numbers in this subgroup. Cervical samples were
also not tested separately for HIV-1 DNA, a measurement of HIV-1-infected cells, which
could persist in inflamed cervical secretions despite ART [14,20].
In conclusion, no significant increase in HIV-1 RNA cervical shedding was found at 2 and 4
weeks after cryotherapy among HIV-positive women diagnosed with CIN 2/3 disease. The
risk of shedding and HIV-1 transmission after cryotherapy may, therefore, not be significant,
particularly among women already on ARTat the time of cervical treatment. This is
generally reassuring and supports the scale-up of `see and treat' programs at HIV treatment
clinics across Africa, but further studies are needed in order to understand more clearly the
risk of HIV-1 cervical shedding among women not receiving ART at the time of
cryotherapy.
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Fig. 1. Mean and 95% confidence interval of log10 cervical HIV-1 RNA viral load by weeks since
cryotherapy
Vertical lines are 95% confidence intervals (CIs) and horizontal lines are interpolation lines
between the mean values. Dashed line = on antiretroviral therapy (ART); solid line = off
ART.
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Table 1
Baseline clinical and socio-demographic characteristics.
Characteristics N Median or N (IQR or %)
Age (years) 50 38 (34–45)
CD4 cell count (cells/μl) 50 296 (178–403)
 On ART 40 289 (177–414)
 Off ART 10 319 (213–375)
CD4 cell count (cells/μl) 50
 0–199 13 (26%)
 201–499 29 (58%)
 ≥500 8 (16%)
Plasma HIV-1 RNA (log10 copies/ml) 50 1.18 (1.18–3.25)
 On ART 40 1.18 (1.18–1.68)
 Off ART 10 4.09 (3.74–4.81)
Weight (kg) 50 59 (52–69)
WHO stage 49
 I 15 (31%)
 II 10 (20%)
 III 21 (43%)
 IV 3 (6%)
Marital status 50
 Married 22 (44%)
 Single 12 (24%)
 Divorced/separated 12 (24%)
 Widowed 4 (8%)
Education level
 None 2 (4%)
 Primary 50 10 (20%)
 Secondary 24 (48%)
 College 14 (28%)
Employment 50
 Employed 40 (80%)
 Unemployed 10 (20%)
No. of lifetime sexual partners
 1 36 23 (64%)
 2 8 (22%)
 ≥3 5 (14%)
On ART 50
 Yes 40 (80%)
 No 10 (20%)
Duration on ART (days) 40 529 (108–1048)
ART, antiretroviral therapy; IQR, interquartile range.
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